Eqis Capital Management Inc. purchased a new position in USANA Health Sciences, Inc. (NYSE:USNA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,270 shares of the company’s stock, valued at approximately $210,000.
A number of other institutional investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in shares of USANA Health Sciences by 7.9% in the first quarter. Renaissance Technologies LLC now owns 1,761,666 shares of the company’s stock worth $101,472,000 after buying an additional 128,766 shares in the last quarter. Teachers Advisors LLC increased its position in shares of USANA Health Sciences by 137.7% in the fourth quarter. Teachers Advisors LLC now owns 217,677 shares of the company’s stock worth $13,322,000 after buying an additional 126,090 shares in the last quarter. Norges Bank acquired a new position in shares of USANA Health Sciences during the fourth quarter worth $6,855,000. FMR LLC boosted its stake in USANA Health Sciences by 7.1% in the first quarter. FMR LLC now owns 1,538,110 shares of the company’s stock worth $88,595,000 after buying an additional 102,086 shares during the last quarter. Finally, State Street Corp boosted its stake in USANA Health Sciences by 104.3% in the fourth quarter. State Street Corp now owns 190,838 shares of the company’s stock worth $11,676,000 after buying an additional 97,430 shares during the last quarter. 43.57% of the stock is owned by institutional investors.
Shares of USANA Health Sciences, Inc. (NYSE:USNA) opened at 56.55 on Friday. The stock has a market cap of $1.38 billion, a PE ratio of 14.69 and a beta of 1.10. USANA Health Sciences, Inc. has a one year low of $52.55 and a one year high of $75.00. The company has a 50-day moving average of $60.17 and a 200 day moving average of $60.33.
USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, July 25th. The company reported $0.98 EPS for the quarter, missing the consensus estimate of $1.06 by $0.08. The company had revenue of $257.10 million for the quarter, compared to analysts’ expectations of $273.61 million. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. USANA Health Sciences’s revenue for the quarter was down .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.07 earnings per share. On average, analysts predict that USANA Health Sciences, Inc. will post $3.79 earnings per share for the current year.
USANA Health Sciences declared that its board has approved a share buyback plan on Tuesday, July 25th that authorizes the company to buyback $64.60 million in shares. This buyback authorization authorizes the company to reacquire up to 46% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/08/19/3270-shares-in-usana-health-sciences-inc-usna-acquired-by-eqis-capital-management-inc-updated-updated.html.
A number of equities research analysts have recently commented on USNA shares. Pivotal Research reiterated a “hold” rating and set a $55.00 price target (down previously from $75.00) on shares of USANA Health Sciences in a report on Monday, May 1st. BidaskClub cut shares of USANA Health Sciences from a “hold” rating to a “sell” rating in a report on Sunday, July 16th.
In related news, insider Paul A. Jones sold 9,851 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $64.50, for a total value of $635,389.50. Following the completion of the transaction, the insider now owns 6,020 shares of the company’s stock, valued at approximately $388,290. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Myron W. Wentz sold 40,000 shares of the business’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $64.99, for a total transaction of $2,599,600.00. The disclosure for this sale can be found here. Insiders sold a total of 171,334 shares of company stock worth $10,413,675 over the last quarter. Insiders own 53.20% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
What are top analysts saying about USANA Health Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for USANA Health Sciences Inc. and related companies.